~~<i id='5B8AFC65E8'><strike id='5B8AFC65E8'><tt id='5B8AFC65E8'><pre id='5B8AFC65E8'></pre></tt></strike></i>~~

Home» comprehensive» Wikipedia

Wikipedia

author：explore 2025-09-28 17:53:20 Page View：6

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Will an HIV vaccine ever be a reality?
Next article： Medical records are filled with copy

explore

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

European officials brace for rough respiratory virus season

FinnbarrWebster/GettyImagesLONDON—HealthofficialsintheU.K.andEuropearerampinguptheircampaignsurginge

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Medicare innovation center doesn’t save money, experts say

AdobeWASHINGTON—AkeyObama-erainitiativewassupposedtosaveMedicaremoneybytestingnewpoliciesforcuttingh